Related Experiment Video
Updated: Mar 1, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Optimal Antiplatelet Therapy in ST-Segment Elevation Myocardial Infarction
1Department of Cardiology, The Mount Sinai Hospital, One Gustave L. Levy Place, New York, NY 10029-6574, USA.
Insights
Antiplatelet therapy is crucial for treating myocardial infarction (MI). This review focuses on the current use of antiplatelet agents in ST-segment elevation MI, a significant advancement in cardiovascular disease treatment.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Cardiovascular disease is a leading global cause of mortality.
- Decreased myocardial infarction (MI) case-fatality rates in the US are attributed to improved acute MI treatments and secondary prevention.
- Antiplatelet therapy is fundamental in managing MI.
Purpose of the Study:
- To review the current landscape of antiplatelet therapy.
- To specifically address its application in ST-segment elevation myocardial infarction (STEMI).
Main Methods:
- Literature review of current antiplatelet therapies.
- Focus on evidence pertaining to STEMI management.
Main Results:
- Antiplatelet therapy remains a cornerstone in MI treatment.
- Advances in secondary prevention have significantly reduced MI mortality.
- Current strategies for STEMI involve specific antiplatelet regimens.
Conclusions:
- Antiplatelet therapy is essential for STEMI patients.
- Ongoing research and clinical practice evolve antiplatelet strategies for better outcomes in MI.
Abstract:
Cardiovascular disease is the leading cause of death worldwide. Case-fatality rates for myocardial infarction (MI) in the United States have decreased over the past decades, in large part due to advances in the treatment of acute MI and secondary preventive therapy after MI. Antiplatelet therapy remains the cornerstone of treatment of MI. This article reviews the current state of antiplatelet therapy in ST-segment elevation MI.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome I: Introduction
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Angina IV: Management

